FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094552700> ?p ?o ?g. }

• W3094552700 endingPage "e928" @default.
• W3094552700 startingPage "e927" @default.
• W3094552700 abstract "In this study, it was aimed to evaluate the toxicity and effectiveness of gemcitabine administration in concomitant chemo-radiotherapy in muscle invasive bladder cancer. A total of 41 patients with muscle invasive bladder cancer were included into the study who had been treated with concomitant chemo-radiotherapy at radiation oncology department of Uludağ University Medical School between 2005 and 2018. The evaluation was done retrospectively. Six (15%) of the cases were female and 35 (85%) were male and the median age was 69(median 40-89) years. Histological diagnosis was transitional cell carcinoma in 37 patients whereas squamous component was detected in 4 patients. Radiotherapy five days a week with 1,8 Gy fraction doses after applying to 45 Gy to primary tumors and lymphatics in total, 5,4-21,6 Gy boost dose was applied to primary tumors. Radiotherapy planning were done using three dimensional or volumetric arc therapy techniques. Gemcitabine, used in concomitant chemo-radiotherapy, was administered at a dose of 250-350 mg/m2 once a week. Toxicity assessment was performed weekly during the treatment process. Control cystoscopy a biopsy was performed 3 months after radiotherapy to evaluate treatment effectiveness. IBM SPSS v.20 program for statistical analysis was used. Cystoscopic evaluation could be performed in 31 patients and complete response was found in 26 (83,8%) of these patients. After a median follow-up of 24 months (range 3-80). Locoregional and distant recurrence were detected in 9 (23%) patients and 10 (26%) patients, respectively. In the analysis made using the Kaplan-Meier survival analysis method. 2 years overall survival was 39 % and disease-free survival was 54%. It was determined that age (p = 0,038), histological type (p = 0,011) and total radiotherapy dose was ≥60 Gy (p = 0,042) were effective factors for survival. Grade 3 leucopenia was observed in 4 (9%) cases and grade3-4 thrombocytopenia 7 (17%) cases associated with treatment. Grade 3 gastro intestinal toxicity associated with chemo-radiotherapy was observed in 7 (17%) cases and grade 3 genitourinary system side effect was observed in 3(7%) cases and chemotherapy was omitted at that week. Concomitant chemo-radiotherapy is a safe and effective method in the curative treatment of muscle invasive bladder cancer. Gemcitabine is an effective alternative in concurrent administration in patients who cannot be administered cisplatin due to renal dysfunction." @default.
• W3094552700 created "2020-10-29" @default.
• W3094552700 creator A5008195633 @default.
• W3094552700 creator A5055636982 @default.
• W3094552700 creator A5055731576 @default.
• W3094552700 creator A5089612307 @default.
• W3094552700 date "2020-11-01" @default.
• W3094552700 modified "2023-09-27" @default.
• W3094552700 title "Toxicity And Efficacy Results Of Gemcitabine Administration In Concomitant Chemo-Radiotherapy In Muscle Invasive Bladder Cancer" @default.
• W3094552700 doi "https://doi.org/10.1016/j.ijrobp.2020.07.581" @default.
• W3094552700 hasPublicationYear "2020" @default.
• W3094552700 type Work @default.
• W3094552700 sameAs 3094552700 @default.
• W3094552700 citedByCount "0" @default.
• W3094552700 crossrefType "journal-article" @default.
• W3094552700 hasAuthorship W3094552700A5008195633 @default.
• W3094552700 hasAuthorship W3094552700A5055636982 @default.
• W3094552700 hasAuthorship W3094552700A5055731576 @default.
• W3094552700 hasAuthorship W3094552700A5089612307 @default.
• W3094552700 hasBestOaLocation W30945527001 @default.
• W3094552700 hasConcept C121608353 @default.
• W3094552700 hasConcept C126322002 @default.
• W3094552700 hasConcept C126894567 @default.
• W3094552700 hasConcept C141071460 @default.
• W3094552700 hasConcept C2779384505 @default.
• W3094552700 hasConcept C2780258809 @default.
• W3094552700 hasConcept C2780352672 @default.
• W3094552700 hasConcept C29730261 @default.
• W3094552700 hasConcept C509974204 @default.
• W3094552700 hasConcept C71924100 @default.
• W3094552700 hasConceptScore W3094552700C121608353 @default.
• W3094552700 hasConceptScore W3094552700C126322002 @default.
• W3094552700 hasConceptScore W3094552700C126894567 @default.
• W3094552700 hasConceptScore W3094552700C141071460 @default.
• W3094552700 hasConceptScore W3094552700C2779384505 @default.
• W3094552700 hasConceptScore W3094552700C2780258809 @default.
• W3094552700 hasConceptScore W3094552700C2780352672 @default.
• W3094552700 hasConceptScore W3094552700C29730261 @default.
• W3094552700 hasConceptScore W3094552700C509974204 @default.
• W3094552700 hasConceptScore W3094552700C71924100 @default.
• W3094552700 hasIssue "3" @default.
• W3094552700 hasLocation W30945527001 @default.
• W3094552700 hasOpenAccess W3094552700 @default.
• W3094552700 hasPrimaryLocation W30945527001 @default.
• W3094552700 hasRelatedWork W1990109374 @default.
• W3094552700 hasRelatedWork W2029780593 @default.
• W3094552700 hasRelatedWork W2073474629 @default.
• W3094552700 hasRelatedWork W2108667718 @default.
• W3094552700 hasRelatedWork W2401908859 @default.
• W3094552700 hasRelatedWork W2410406217 @default.
• W3094552700 hasRelatedWork W2890299839 @default.
• W3094552700 hasRelatedWork W3094552700 @default.
• W3094552700 hasRelatedWork W4313197990 @default.
• W3094552700 hasRelatedWork W2118673085 @default.
• W3094552700 hasVolume "108" @default.
• W3094552700 isParatext "false" @default.
• W3094552700 isRetracted "false" @default.
• W3094552700 magId "3094552700" @default.
• W3094552700 workType "article" @default.